United Therapeutics Corporation (UTHR) has been under a strong bear grip, hence the stock is down -1.75% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.44% in the past 1 week. The stock has risen by 0.94% in the past week indicating that the buyers are active at lower levels, but the stock is down -1.88% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 1.65% and the 50-Day Moving Average is 4.93%.The 200 Day SMA reached 1.41%. United Therapeutics Corporation is up 3.02% in the last 3-month period. Year-to-Date the stock performance stands at -21.52%.
United Therapeutics Corporation (NASDAQ:UTHR): The stock opened in the green at $123.36 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $123.49 and a low of $121.58 for the day. The stock did not find buyers even at the lows and closed at $122.91 recording a loss of -0.24%. 442,952 shares exchanged hands during the trading day. The stock had closed at $123.21 in the previous days trading.
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.